Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Mineralys Therapeutics (NASDAQ:MLYS)

Mineralys Therapeutics (NASDAQ:MLYS) and Tenaya Therapeutics (NASDAQ:TNYA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mineralys Therapeutics and Tenaya Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1	1	6	0	2.62
Tenaya Therapeutics	1	0	5	1	2.86

Mineralys Therapeutics currently has a consensus price target of $49.33, suggesting a potential upside of 84.70%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 388.88%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Mineralys Therapeutics.

Earnings & Valuation

This table compares Mineralys Therapeutics and Tenaya Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65 million	($2.05)	-13.03
Tenaya Therapeutics	N/A	N/A	-$90.60 million	($0.47)	-1.74

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mineralys Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500.

Insider and Institutional Ownership

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Mineralys Therapeutics and Tenaya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats Mineralys Therapeutics on 8 of the 12 factors compared between the two stocks.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.